Small Molecule Drug Problems
Small molecule drugs offer a fantastic alternative to traditional treatments. However, the rate at which new drugs are researched and developed is very slow, with many of them failing at clinical phases. This sluggish progress is mainly due to the limitations associated with small-molecule drugs and the limited experience in the field. One significant limitation is the development of drug resistance by the body after a period of clinical use. Drug resistance is primarily caused by gene mutations, amplifications, and apoptosis, which hinder the effectiveness of anti-cancer drugs over time.
Problems With Treatment
Some problems arise with small molecule drug treatment. Over time, the body may develop resistance to these drugs, diminishing their effectiveness in combating cancer. The slow pace of research and development in this area can also lead to delays in introducing new drugs to the market, limiting treatment options for patients. Furthermore, targeting specific molecular pathways or achieving adequate drug concentrations at the tumor site can pose challenges, affecting treatment success. While small molecule drugs generally cause fewer severe side effects compared to traditional chemotherapy, concerns about side effects and toxicity persist and require careful consideration.
